Pfizer Inc. (NYSE:PFE) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,713 shares of the biopharmaceutical company’s stock after selling 886 shares during the period. Great Lakes Advisors LLC’s holdings in Pfizer were worth $443,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Hopwood Financial Services Inc. acquired a new position in Pfizer in the fourth quarter worth approximately $56,000. EverSource Wealth Advisors LLC raised its position in shares of Pfizer by 1.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 35,435 shares of the biopharmaceutical company’s stock worth $940,000 after purchasing an additional 500 shares during the period. Summit X LLC lifted its holdings in shares of Pfizer by 15.6% during the fourth quarter. Summit X LLC now owns 14,756 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 1,989 shares during the last quarter. Natural Investments LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $534,000. Finally, Donaldson Capital Management LLC raised its holdings in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after buying an additional 410 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.5 %

PFE stock opened at $25.74 on Monday. The firm has a market cap of $145.85 billion, a PE ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a fifty day simple moving average of $26.24 and a 200 day simple moving average of $27.12. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 EPS. The firm’s revenue was up 24.7% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.